Binney Street Capital
Binney Street Capital, founded in 2021, serves as the corporate venture arm of the Dana-Farber Cancer Institute in Boston, Massachusetts. The organization is dedicated to advancing the development of innovative research and technologies aimed at treating uncurable diseases by investing in startup companies affiliated with Dana-Farber. Binney Street Capital focuses on sectors such as therapeutics, novel diagnostics, digital health, life sciences, and healthcare services. The firm seeks to foster early-stage ventures that can contribute to significant advancements in medical treatments and diagnostics. Through its strategic investments, Binney Street Capital aims to support the growth of companies that are at the forefront of healthcare innovation.
4 past transactions
NextPoint Therapeutics
Series B in 2024
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.
Precede Biosciences
Series A in 2023
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.
NextPoint Therapeutics
Series B in 2023
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.
Kojin Therapeutics
Series A in 2021
Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.